Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit
about
Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activationThe link between androgen receptor splice variants and castration-resistant prostate cancer.Molecular pathways and targets in prostate cancerNiclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancerHydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in miceTargeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapiesMechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer.Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain.Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression.The evolution of prostate cancer therapy: targeting the androgen receptorSwitching and withdrawing hormonal agents for castration-resistant prostate cancer.Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancerA novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery.NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer.Sigma1 Pharmacology in the Context of Cancer.(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer.Positive feedback loop mediated by protein phosphatase 1α mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer.Androgen receptor variants: another twist in the plot.Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A pre-clinical study.Tri-nucleotide consortium of androgen receptor is associated with low serum FSH and testosterone in asthenospermic men.Longer trinucleotide repeats of androgen receptor are associated with higher testosterone and low oxytocin levels in diabetic premature ejaculatory dysfunction patients.Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
P2860
Q27007208-F4B8B503-D0F4-42F0-A300-6A235370BA9DQ30618562-1A459F86-B6A5-4D18-BAF3-60EE624184A6Q34365632-DE6CBB00-13E3-4357-8551-981A65DDA6F8Q35150756-EBB4F308-5C9B-4A3E-A9B5-17CA29017B51Q35742486-3164A85B-1CAC-45CA-8DF5-0AFB24A6D753Q35842471-81CC4A0D-2B4B-4C64-B435-F67F3E040684Q36055229-C89C0EF2-AECA-40C0-BD4E-8313324DC4C6Q37270422-4CF88C11-4975-4136-AC99-A3B8C828162CQ37638982-3967FD6F-BD81-4416-9217-FBDB2E54987FQ37691775-16BD3F47-DE5E-4A7E-BF49-6FB1608C67AAQ38242231-4EE2AAF0-F6E3-408A-9CF6-2744669DB5D5Q38266909-4B7EF832-F6CC-4476-A5C0-DD4E13C201E1Q38309205-48E3F663-F0EB-42E1-9B25-BC246FF9D61EQ38469746-7184AACA-C2A0-430F-ABCF-11B4285E38D3Q38723579-B43AE4E0-8EB6-43AC-8B5B-B96955F2B29CQ38732922-CB288284-C529-456E-8557-F19AA76FB130Q38838223-E49A7E17-9E00-48C1-92A1-E0A1C39D8365Q38865962-FB2DEAF4-2235-4F88-A1D3-6C83C00241E5Q38943216-955F0B73-5A9D-4799-BAB8-27F3A3EECF12Q39458668-1BE407B1-C73F-4E9D-A705-3991FE73784FQ41161118-A005048A-662D-4EA8-95D4-9103BB427CDAQ41474636-50852A5D-1E2F-465A-B809-FA6434FF2C86Q41832140-5852E230-311C-47FF-91F4-571A1E425B31Q42006129-B8DA7954-E401-4AFA-862B-588061D92CE7Q42371309-E78F1831-B566-4F0A-9401-E3B46193176CQ48255570-2AA4E8C3-BF1C-4516-A580-02E7800033CAQ48565123-9FC6F426-F284-4F75-9FE2-7062CA53A3CAQ52349523-9AB24FD7-FF09-4E42-AC84-4FD96024FB14Q52637922-4D71217B-008F-45C5-AC60-951FA98E5650Q58698705-A05229DE-3E6C-4F8D-9071-4578B6881B6B
P2860
Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit
@en
Molecular pathways: targeting ...... eptor for therapeutic benefit.
@nl
type
label
Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit
@en
Molecular pathways: targeting ...... eptor for therapeutic benefit.
@nl
prefLabel
Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit
@en
Molecular pathways: targeting ...... eptor for therapeutic benefit.
@nl
P2093
P2860
P1476
Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit
@en
P2093
Bruce Montgomery
Elahe A Mostaghel
Stephen R Plymate
P2860
P304
P356
10.1158/1078-0432.CCR-12-3601
P407
P577
2013-12-04T00:00:00Z